PT3782612T - Formulações orais de análogos da citidina e métodos de utilização dos mesmos - Google Patents

Formulações orais de análogos da citidina e métodos de utilização dos mesmos

Info

Publication number: PT3782612T
Authority: PT; Portugal
Prior art keywords: methods; oral formulations; cytidine analogs; cytidine; analogs
Prior art date: 2008-05-15

Application number

PT202011433T

Other languages

English (en)

Original Assignee

Celgene Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-05-15

Filing date

2009-05-14

Publication date

2024-01-18

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40941609&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3782612(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-05-14 Application filed by Celgene Corp filed Critical Celgene Corp

2024-01-18 Publication of PT3782612T publication Critical patent/PT3782612T/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biophysics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oil, Petroleum & Natural Gas (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biochemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PT202011433T 2008-05-15 2009-05-14 Formulações orais de análogos da citidina e métodos de utilização dos mesmos PT3782612T (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date
US5360908P	2008-05-15	2008-05-15
US20114508P	2008-12-05	2008-12-05
US15787509P	2009-03-05	2009-03-05

Publications (1)

Publication Number	Publication Date
PT3782612T true PT3782612T (pt)	2024-01-18

Family

ID=40941609

Family Applications (5)

Application Number	Title	Priority Date	Filing Date
PT192131480T PT3692983T (pt)	2008-05-15	2009-05-14	Formulações orais de análogos da citidina e métodos de utilização dos mesmos
PT202011052T PT3782611T (pt)	2008-05-15	2009-05-14	Formulações orais de análogos da citidina e métodos de utilização dos mesmos
PT09746975T PT2299984T (pt)	2008-05-15	2009-05-14	Formulações orais de análogos da citidina e métodos da sua utilização
PT202011433T PT3782612T (pt)	2008-05-15	2009-05-14	Formulações orais de análogos da citidina e métodos de utilização dos mesmos
PT131827214T PT2695609T (pt)	2008-05-15	2009-05-14	Formulações orais de análogos da citidina e métodos de utilização dos mesmos

Family Applications Before (3)

Application Number	Title	Priority Date	Filing Date
PT192131480T PT3692983T (pt)	2008-05-15	2009-05-14	Formulações orais de análogos da citidina e métodos de utilização dos mesmos
PT202011052T PT3782611T (pt)	2008-05-15	2009-05-14	Formulações orais de análogos da citidina e métodos de utilização dos mesmos
PT09746975T PT2299984T (pt)	2008-05-15	2009-05-14	Formulações orais de análogos da citidina e métodos da sua utilização

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PT131827214T PT2695609T (pt)	2008-05-15	2009-05-14	Formulações orais de análogos da citidina e métodos de utilização dos mesmos

Country Status (34)

Country	Link
US (11)	US8846628B2 (pt)
EP (6)	EP2695609B1 (pt)
JP (3)	JP2011520880A (pt)
KR (1)	KR101633134B1 (pt)
CN (3)	CN103479586B (pt)
AR (1)	AR071808A1 (pt)
AU (3)	AU2009246926B2 (pt)
BR (1)	BRPI0912717A2 (pt)
CA (3)	CA2761582C (pt)
CL (2)	CL2009001170A1 (pt)
CO (1)	CO6300930A2 (pt)
CR (1)	CR11789A (pt)
CY (3)	CY1121350T1 (pt)
DK (5)	DK3692983T3 (pt)
EC (1)	ECSP10010665A (pt)
ES (5)	ES2774226T3 (pt)
FI (1)	FI3782612T3 (pt)
HR (5)	HRP20221064T1 (pt)
HU (5)	HUE059635T2 (pt)
IL (2)	IL238087B (pt)
LT (5)	LT3782612T (pt)
MX (2)	MX2010012470A (pt)
MY (1)	MY161593A (pt)
NI (1)	NI201000193A (pt)
NZ (3)	NZ589437A (pt)
PE (2)	PE20091971A1 (pt)
PL (5)	PL2299984T3 (pt)
PT (5)	PT3692983T (pt)
RU (3)	RU2476207C2 (pt)
SG (1)	SG193206A1 (pt)
SI (5)	SI2695609T1 (pt)
TW (3)	TWI522103B (pt)
WO (1)	WO2009139888A1 (pt)
ZA (1)	ZA201008229B (pt)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8404716B2 (en)	2002-10-15	2013-03-26	Celgene Corporation	Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US8404717B2 (en) *	2002-10-15	2013-03-26	Celgene Corporation	Methods of treating myelodysplastic syndromes using lenalidomide
US11116782B2 (en)	2002-10-15	2021-09-14	Celgene Corporation	Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US6887855B2 (en)	2003-03-17	2005-05-03	Pharmion Corporation	Forms of 5-azacytidine
US6943249B2 (en)	2003-03-17	2005-09-13	Ash Stevens, Inc.	Methods for isolating crystalline Form I of 5-azacytidine
US8497292B2 (en) *	2005-12-28	2013-07-30	Translational Therapeutics, Inc.	Translational dysfunction based therapeutics
EP2211870A1 (en) *	2007-11-01	2010-08-04	Celgene Corporation	Cytidine analogs for treatment of myelodysplastic syndromes
US20150290228A1 (en) *	2008-05-15	2015-10-15	Jay T. BACKSTROM	Oral formulations of cytidine analogs and methods of use thereof
PL2299984T3 (pl)	2008-05-15	2019-07-31	Celgene Corporation	Doustne formulacje analogów cytydyny i sposoby ich zastosowania
CA2789365A1 (en)	2009-02-10	2010-08-19	Celgene International Sarl	Methods for treating non-small cell lung cancer using 5-azacytidine
US8491927B2 (en)	2009-12-02	2013-07-23	Nimble Epitech, Llc	Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
US8759303B2 (en)	2010-06-07	2014-06-24	Telik, Inc.	Compositions and methods for treating myelodysplastic syndrome
US20110301102A1 (en) *	2010-06-07	2011-12-08	Telik, Inc.	Compositions and methods for treating myelodysplastic syndrome
MY166014A (en) *	2010-06-07	2018-05-21	Abraxis Bioscience Llc	Combination therapy methods for treating proliferative diseases
CN103338753A (zh)	2011-01-31	2013-10-02	细胞基因公司	胞苷类似物的药物组合物及其使用方法
EP2481813A1 (en) *	2011-02-01	2012-08-01	Centro di Riferimento Oncologico - Istituto Nazionale Tumori - Aviano	Markers of cutaneous melanoma and uses thereof
RU2013148580A (ru)	2011-03-31	2015-05-10	Селджин Интернешнл Сарл	Синтез 5-азацитидина
MX2014005314A (es) *	2011-11-01	2014-09-08	Celgene Corp	Metodos para tratar canceres utilizando formulaciones orales de analogos de citidina.
JP6231988B2 (ja)	2011-11-03	2017-11-15	ミレニアムファーマシューティカルズ，インコーポレイテッドＭｉｌｌｅｎｎｉｕｍＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	Ｎｅｄｄ８活性化酵素阻害剤および低メチル化剤の投与
US9474779B2 (en)	2012-01-19	2016-10-25	Agios Pharmaceuticals, Inc.	Therapeutically active compositions and their methods of use
WO2014015153A2 (en) *	2012-07-20	2014-01-23	Star Biotechnology, Llc	Compositions and methods for treating ewing's sarcoma and other disorders related to ews-fli1
US20150031627A1 (en)	2013-07-25	2015-01-29	Agios Pharmaceuticals, Inc	Therapeutically active compounds and their methods of use
EA036325B1 (ru)	2014-03-14	2020-10-27	Аджиос Фармасьютикалз, Инк.	Фармацевтическая композиция на основе твердой дисперсии ингибитора idh1
WO2015195634A1 (en)	2014-06-17	2015-12-23	Celgne Corporation	Methods for treating epstein-barr virus (ebv) associated cancers using oral formulations of 5-azacytidine
EP3182996B1 (en)	2014-08-22	2022-12-28	Celgene Corporation	Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies
CA2986522A1 (en) *	2015-05-22	2016-12-01	Novartis Ag	Pharmaceutical compositions
SG11201803091PA (en)	2015-10-15	2018-05-30	Agios Pharmaceuticals Inc	Combination therapy for treating malignancies
WO2017066611A1 (en) *	2015-10-15	2017-04-20	Celgene Corporation	Combination therapy for treating malignancies
ES2981538T3 (es)	2015-10-15	2024-10-09	Servier Lab	Terapia de combinación que comprende ivosidenib, citarabina y daunorrubicina o idarrubicina para el tratamiento de leucemia mielógena aguda
MX2021007569A (es)	2015-12-03	2022-06-09	Epidestiny Inc	Composiciones que contienen decitabina, 5azacitidina y tetrahidrouridina y sus usos.
WO2017180489A1 (en)	2016-04-12	2017-10-19	The Johns Hopkins University	Quantitative determination of nucleoside analogue drugs in genomic dna or rna
US10980788B2 (en)	2018-06-08	2021-04-20	Agios Pharmaceuticals, Inc.	Therapy for treating malignancies
EA039874B1 (ru) *	2019-06-06	2022-03-22	Общество С Ограниченной Ответственностью "Технология Лекарств"	Композиция помалидомида для лечения заболеваний, ассоциированных с фактором некроза опухоли (фно)
US20220249528A1 (en) *	2019-06-20	2022-08-11	Celgene Corporation	Azacitidine in combination with venetoclax, gilteritinib, midostaurin or other compounds for treating leukemia or myelodysplastic syndrome
JP2022553306A (ja)	2019-10-21	2022-12-22	ノバルティスアーゲー	Ｔｉｍ－３阻害剤およびその使用
BR112022007376A2 (pt)	2019-10-21	2022-07-05	Novartis Ag	Terapias de combinação com venetoclax e inibidores de tim-3
IL293834A (en)	2019-12-20	2022-08-01	Novartis Ag	A combination of anti-tim-3 antibody mbg453 and anti, nis793 tgf-beta antibody with or without decitabine or anti-pd-1 antibody spratlizumab, for the treatment of myelofibrosis and myelodysplastic syndrome
EP4090335A1 (en)	2020-01-17	2022-11-23	Novartis AG	Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
EP4185583A4 (en)	2020-07-23	2024-10-30	Southern Res Inst	POLYMORPHS OF 5-AZA-4'-THIO-2'-DEOXYCYTIDINE
EP4262812A1 (en)	2020-12-18	2023-10-25	Southern Research Institute	6-aza-nucleoside prodrugs as antiviral agents for treating virus infections
WO2022192621A1 (en)	2021-03-12	2022-09-15	Celgene Corporation	Methods for using a hypomethylating agent to treat diseases and disorders based on gene mutation profiles
CA3236051A1 (en)	2021-10-19	2023-04-27	Akirabio, Inc.	Compositions comprising 2'-deoxycytidine analogs and use thereof for the treatment of sickle cell disease, thalassemia, and cancers

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2913408A (en)	1956-12-28	1959-11-17	Dow Chemical Co	Corrosion inhibitors for ferrous metals in aqueous solutions of non-oxidizing acids
GB1050899A (pt) *	1963-12-22
CH527207A (de)	1968-05-08	1972-08-31	Ceskoslovenska Akademie Ved	Verfahren zur Herstellung von 1-Glycosyl-5-azacytosinen
CH507969A (de)	1968-11-12	1971-05-31	Ceskoslovenska Akademie Ved	Verfahren zur Herstellung von 1-Glycosyl-5-azacytosinen
DE2012888C3 (de) *	1970-03-14	1981-04-02	Schering Ag, 1000 Berlin Und 4619 Bergkamen	Verfahren zur Herstellung von 5-Azapyrimidinnucleosiden
FR2123632A6 (en)	1971-01-26	1972-09-15	Ceskoslovenska Akademie Ved	Prepn of 5-azacytosines and 5-azacytidines - from bis trimethylsilyl-5-azacytosine
DE2122991C2 (de) *	1971-05-04	1982-06-09	Schering Ag, 1000 Berlin Und 4619 Bergkamen	Verfahren zur Herstellung von Cytosin- und 6-Azacytosinnucleosiden
DE2508312A1 (de) *	1975-02-24	1976-09-02	Schering Ag	Neues verfahren zur herstellung von nucleosiden
DE2757365A1 (de) *	1977-12-20	1979-06-21	Schering Ag	Neues verfahren zur herstellung von nucleosiden
JPS59151784U (ja)	1983-03-30	1984-10-11	日産自動車株式会社	トラツクのリヤボデイ構造
US5391485A (en)	1985-08-06	1995-02-21	Immunex Corporation	DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
JPS63500636A (ja)	1985-08-23	1988-03-10	麒麟麦酒株式会社	多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
US4810643A (en)	1985-08-23	1989-03-07	Kirin- Amgen Inc.	Production of pluripotent granulocyte colony-stimulating factor
EP0397042B1 (de)	1989-05-10	1995-08-16	F. Hoffmann-La Roche Ag	Herstellung von Isochinolinderivaten
US5360352A (en)	1992-12-24	1994-11-01	The Whitaker Corporation	Wire retainer for current mode coupler
US6432924B1 (en) *	1993-12-26	2002-08-13	East Carolina University	Method of treating disorders characterized by overexpression of cytidine deaminase or deoxycytidine deaminase
GB9412394D0 (en) *	1994-06-21	1994-08-10	Danbiosyst Uk	Colonic drug delivery composition
US5700640A (en) *	1994-09-16	1997-12-23	Basf Aktiengesellschaft	Inducers of gamma globin gene expression and screening assays therefor
US5539209A (en)	1994-10-17	1996-07-23	Trojan Technologies Inc.	Method of cleaning fouling materials from a radiation module
EP1027359B9 (en) *	1996-10-16	2003-09-17	Ribapharm, Inc.	Monocyclic l-nucleosides, analogs and uses thereof
CA2290624C (en)	1997-06-06	2006-12-05	John W. Shell	Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
US6635280B2 (en) *	1997-06-06	2003-10-21	Depomed, Inc.	Extending the duration of drug release within the stomach during the fed mode
US6200604B1 (en)	1998-03-27	2001-03-13	Cima Labs Inc.	Sublingual buccal effervescent
US6566395B1 (en)	1999-05-25	2003-05-20	Biomedicines, Inc.	Methods of treating proliferative disorders
US6803195B1 (en)	1999-07-02	2004-10-12	Ramot At Tel-Aviv University Ltd.	Facile detection of cancer and cancer risk based on level of coordination between alleles
AU6015400A (en) *	1999-07-16	2001-02-05	Amato Pharmaceutical Products, Ltd.	Glycyrrhizin preparations for transmucosal absorption
US20030180352A1 (en)	1999-11-23	2003-09-25	Patel Mahesh V.	Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
ATE340563T1 (de)	2000-02-04	2006-10-15	Depomed Inc	DOSIERUNGSFORM DES TYPS ßHÜLLE UND KERNß MIT EINER WIRKSTOFFFREISETZUNG, DIE SICH DER NULLTEN ORDNUNG ANNÄHERT
GB0102342D0 (en) *	2001-01-30	2001-03-14	Smithkline Beecham Plc	Pharmaceutical formulation
EP1399159A4 (en)	2001-06-01	2007-02-14	Cytovia Inc	4-SUBSTITUTE-1- (ARYLMETHYLIDENE) THIOSEMICARBAZIDE, 4-SUBSTITUTE-1- (ARYLCARBONYL) THIOSEMICARBAZIDE AND ANALOGUES AS ACTIVATORS OF APOPTOSIS CAPSASES AND TRIGS, AND USE THEREOF
US6723340B2 (en)	2001-10-25	2004-04-20	Depomed, Inc.	Optimal polymer mixtures for gastric retentive tablets
US20030220254A1 (en) *	2002-03-29	2003-11-27	Texas Tech University System	Composition and method for preparation of an oral dual controlled release formulation of a protein and inhibitor
AU2003278904A1 (en) *	2002-09-24	2004-04-19	Kornis Pharmaceuticals, Incorporated	1, 3, 5-triazines for treatment of viral diseases
US7189740B2 (en)	2002-10-15	2007-03-13	Celgene Corporation	Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
WO2004041195A2 (en)	2002-10-31	2004-05-21	Supergen, Inc.	Pharmaceutical formulations targeting specific regions of the gastrointestinal tract
US7144876B2 (en)	2002-12-18	2006-12-05	Cytovia, Inc.	3,5-Disubstituted-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof
US7038038B2 (en) *	2003-03-17	2006-05-02	Pharmion Corporation	Synthesis of 5-azacytidine
US6943249B2 (en)	2003-03-17	2005-09-13	Ash Stevens, Inc.	Methods for isolating crystalline Form I of 5-azacytidine
US6887855B2 (en) *	2003-03-17	2005-05-03	Pharmion Corporation	Forms of 5-azacytidine
AU2004241729A1 (en)	2003-05-21	2004-12-02	Novartis Ag	Combination of histone deacetylase inhibitors with chemotherapeutic agents
EP2226072A1 (en) *	2003-08-29	2010-09-08	Aton Pharma, Inc.	Combinations of suberoylanilide hydroxamic acid and antimetbolic agents for treating cancer
US7192781B2 (en) *	2004-04-13	2007-03-20	Pharmion Corporation	Methods for stabilizing 5-azacytidine in plasma
US20060069060A1 (en) *	2004-09-27	2006-03-30	Sanjeev Redkar	Salts of decitabine
US20060063735A1 (en)	2004-09-17	2006-03-23	Supergen, Inc.	Salts of 5-azacytidine
CN100374160C (zh) *	2004-11-22	2008-03-12	山东蓝金生物工程有限公司	一种含抗代谢类药物的抗癌药物组合物
US20060128654A1 (en) *	2004-12-10	2006-06-15	Chunlin Tang	Pharmaceutical formulation of cytidine analogs and derivatives
EP3698783A1 (en)	2005-02-18	2020-08-26	Abraxis BioScience, LLC	Combinations and modes of administration of therapeutic agents and combination therapy
SI1868579T1 (sl)	2005-03-07	2011-02-28	Bayer Schering Pharma Ag	Farmacevtski sestavek, ki obsega omega-karboksiarilno substituirano difenil sečnino, za zdravljenje raka
CN100500212C (zh) *	2005-04-06	2009-06-17	山东蓝金生物工程有限公司	一种抗实体肿瘤药物组合物
US8058260B2 (en) *	2006-05-22	2011-11-15	Xenoport, Inc.	2′-C-methyl-ribofuranosyl cytidine prodrugs, pharmaceutical compositions and uses thereof
WO2008028193A2 (en)	2006-09-01	2008-03-06	Pharmion Corporation	Colon-targeted oral formulations of cytidine analogs
US7759481B2 (en) *	2007-01-11	2010-07-20	Ivax Corporation	Solid state forms of 5-azacytidine and processes for preparation thereof
EP2114152A1 (en)	2007-01-25	2009-11-11	Nevada Cancer Institute	Use of acetylated or esterificated azacytidine, decitabine, or other nucleoside analogs as oral agents for the treatment of tumors or other dysplastic syndromes sensitive to hypomethylating agents
JP5173298B2 (ja)	2007-07-25	2013-04-03	キヤノン株式会社	プリント配線板およびそれを用いた電子機器
WO2009016617A2 (en)	2007-08-02	2009-02-05	Chemagis Ltd.	Stable highly pure azacitidine and preparation methods therefor
UA99308C2 (ru)	2007-09-26	2012-08-10	Маунт Синай Скул Оф Медсин	Аналог азацитидина и его применение
EP2048151A1 (en) *	2007-10-10	2009-04-15	Cilag AG	Method for producing nucleosides by direct glycosylation of the nucleoside base
JO2778B1 (en)	2007-10-16	2014-03-15	ايساي انك	Certain vehicles, installations and methods
EP2211870A1 (en) *	2007-11-01	2010-08-04	Celgene Corporation	Cytidine analogs for treatment of myelodysplastic syndromes
PL2299984T3 (pl)	2008-05-15	2019-07-31	Celgene Corporation	Doustne formulacje analogów cytydyny i sposoby ich zastosowania
WO2010014883A2 (en) *	2008-08-01	2010-02-04	Dr. Reddy's Laboratories Ltd.	Azacitidine process and polymorphs
EP2324042B1 (en) *	2008-08-06	2012-11-28	Sicor, Inc.	Process for preparing azacytidine intermediate
JP5650643B2 (ja) *	2008-08-08	2015-01-07	サイノファームタイワンリミテッド	５−アザシトシンヌクレオシド及びその誘導体の製造方法
KR101807319B1 (ko)	2008-11-22	2017-12-11	제넨테크, 인크.	유방암의 치료를 위한, 화학요법과 조합된 항-ｖｅｇｆ 항체의 용도
US20110042247A1 (en) *	2009-06-25	2011-02-24	Chandrasekhar Kocherlakota	Formulations of azacitidine and its derivatives
WO2011014541A1 (en)	2009-07-30	2011-02-03	Eagle Pharmaceuticals, Inc.	Stable formulations of azacitidine
IT1399195B1 (it) *	2010-03-30	2013-04-11	Chemi Spa	Processo per la sintesi di azacitidina e decitabina
CN103338753A (zh) *	2011-01-31	2013-10-02	细胞基因公司	胞苷类似物的药物组合物及其使用方法
RU2013148580A (ru)	2011-03-31	2015-05-10	Селджин Интернешнл Сарл	Синтез 5-азацитидина
WO2013022872A1 (en)	2011-08-10	2013-02-14	Celgene Corporation	Gene methylation biomarkers and methods of use thereof
MX2014005314A (es) *	2011-11-01	2014-09-08	Celgene Corp	Metodos para tratar canceres utilizando formulaciones orales de analogos de citidina.

2009
- 2009-05-14 PL PL09746975T patent/PL2299984T3/pl unknown
- 2009-05-14 EP EP13182721.4A patent/EP2695609B1/en active Active
- 2009-05-14 DK DK19213148.0T patent/DK3692983T3/da active
- 2009-05-14 JP JP2011509487A patent/JP2011520880A/ja not_active Withdrawn
- 2009-05-14 EP EP20201105.2A patent/EP3782611B1/en active Active
- 2009-05-14 EP EP20201143.3A patent/EP3782612B1/en active Active
- 2009-05-14 ES ES13182721T patent/ES2774226T3/es active Active
- 2009-05-14 ES ES09746975T patent/ES2712506T3/es active Active
- 2009-05-14 SI SI200932020T patent/SI2695609T1/sl unknown
- 2009-05-14 NZ NZ589437A patent/NZ589437A/xx unknown
- 2009-05-14 US US12/466,213 patent/US8846628B2/en active Active
- 2009-05-14 EP EP23207760.2A patent/EP4327888A3/en active Pending
- 2009-05-14 DK DK20201105.2T patent/DK3782611T3/da active
- 2009-05-14 SI SI200932188T patent/SI3782612T1/sl unknown
- 2009-05-14 PT PT192131480T patent/PT3692983T/pt unknown
- 2009-05-14 HU HUE20201105A patent/HUE059635T2/hu unknown
- 2009-05-14 ES ES20201143T patent/ES2969144T3/es active Active
- 2009-05-14 WO PCT/US2009/002999 patent/WO2009139888A1/en active Application Filing
- 2009-05-14 DK DK13182721.4T patent/DK2695609T3/da active
- 2009-05-14 SI SI200931918T patent/SI2299984T1/sl unknown
- 2009-05-14 LT LTEP20201143.3T patent/LT3782612T/lt unknown
- 2009-05-14 CN CN201310363158.0A patent/CN103479586B/zh not_active Ceased
- 2009-05-14 PT PT202011052T patent/PT3782611T/pt unknown
- 2009-05-14 LT LTEP19213148.0T patent/LT3692983T/lt unknown
- 2009-05-14 RU RU2010151428/15A patent/RU2476207C2/ru active
- 2009-05-14 LT LTEP13182721.4T patent/LT2695609T/lt unknown
- 2009-05-14 HR HRP20221064TT patent/HRP20221064T1/hr unknown
- 2009-05-14 PL PL20201143.3T patent/PL3782612T3/pl unknown
- 2009-05-14 CN CN200980127929.8A patent/CN102099018B/zh not_active Ceased
- 2009-05-14 PT PT09746975T patent/PT2299984T/pt unknown
- 2009-05-14 KR KR1020107028070A patent/KR101633134B1/ko active IP Right Grant
- 2009-05-14 SG SG2013061601A patent/SG193206A1/en unknown
- 2009-05-14 CA CA2761582A patent/CA2761582C/en active Active
- 2009-05-14 BR BRPI0912717-8A2A patent/BRPI0912717A2/pt not_active Application Discontinuation
- 2009-05-14 CN CN201510982946.7A patent/CN105535008A/zh active Pending
- 2009-05-14 ES ES19213148T patent/ES2893785T3/es active Active
- 2009-05-14 CL CL2009001170A patent/CL2009001170A1/es unknown
- 2009-05-14 EP EP09746975.3A patent/EP2299984B1/en active Active
- 2009-05-14 PL PL20201105.2T patent/PL3782611T3/pl unknown
- 2009-05-14 LT LTEP09746975.3T patent/LT2299984T/lt unknown
- 2009-05-14 NZ NZ602833A patent/NZ602833A/en unknown
- 2009-05-14 MX MX2010012470A patent/MX2010012470A/es active IP Right Grant
- 2009-05-14 HR HRP20231439TT patent/HRP20231439T1/hr unknown
- 2009-05-14 DK DK20201143.3T patent/DK3782612T3/da active
- 2009-05-14 CA CA3094580A patent/CA3094580C/en active Active
- 2009-05-14 HU HUE20201143A patent/HUE064677T2/hu unknown
- 2009-05-14 ES ES20201105T patent/ES2927556T3/es active Active
- 2009-05-14 PL PL19213148T patent/PL3692983T3/pl unknown
- 2009-05-14 PT PT202011433T patent/PT3782612T/pt unknown
- 2009-05-14 FI FIEP20201143.3T patent/FI3782612T3/fi active
- 2009-05-14 CA CA3094590A patent/CA3094590A1/en not_active Abandoned
- 2009-05-14 PL PL13182721T patent/PL2695609T3/pl unknown
- 2009-05-14 LT LTEP20201105.2T patent/LT3782611T/lt unknown
- 2009-05-14 PT PT131827214T patent/PT2695609T/pt unknown
- 2009-05-14 SI SI200932143T patent/SI3692983T1/sl unknown
- 2009-05-14 DK DK09746975.3T patent/DK2299984T3/en active
- 2009-05-14 HU HUE09746975A patent/HUE042825T2/hu unknown
- 2009-05-14 NZ NZ623495A patent/NZ623495A/en unknown
- 2009-05-14 MY MYPI2010005331A patent/MY161593A/en unknown
- 2009-05-14 EP EP19213148.0A patent/EP3692983B1/en active Active
- 2009-05-14 AU AU2009246926A patent/AU2009246926B2/en active Active
- 2009-05-14 HU HUE19213148A patent/HUE055911T2/hu unknown
- 2009-05-14 SI SI200932170T patent/SI3782611T1/sl unknown
- 2009-05-14 MX MX2014010978A patent/MX363023B/es unknown
- 2009-05-14 HU HUE13182721A patent/HUE047707T2/hu unknown
- 2009-05-15 PE PE2009000685A patent/PE20091971A1/es not_active Application Discontinuation
- 2009-05-15 PE PE2014002005A patent/PE20142440A1/es not_active Application Discontinuation
- 2009-05-15 AR ARP090101759A patent/AR071808A1/es not_active Application Discontinuation
- 2009-05-15 TW TW098116326A patent/TWI522103B/zh active
- 2009-05-15 TW TW104100098A patent/TW201513869A/zh unknown
- 2009-05-15 TW TW105141639A patent/TWI618538B/zh active
2010
- 2010-11-12 NI NI201000193A patent/NI201000193A/es unknown
- 2010-11-12 CR CR11789A patent/CR11789A/es unknown
- 2010-11-14 IL IL238087A patent/IL238087B/en active IP Right Grant
- 2010-11-14 IL IL209307A patent/IL209307A/en active IP Right Grant
- 2010-11-17 ZA ZA2010/08229A patent/ZA201008229B/en unknown
- 2010-12-07 EC EC2010010665A patent/ECSP10010665A/es unknown
- 2010-12-15 CO CO10157384A patent/CO6300930A2/es not_active Application Discontinuation
2012
- 2012-11-09 RU RU2012147739/15A patent/RU2012147739A/ru unknown
2013
- 2013-04-05 AU AU2013202665A patent/AU2013202665B2/en active Active
- 2013-04-22 CL CL2013001097A patent/CL2013001097A1/es unknown
2014
- 2014-08-19 US US14/463,424 patent/US20150056280A1/en not_active Abandoned
- 2014-12-12 JP JP2014251911A patent/JP6105547B2/ja active Active
2015
- 2015-05-27 AU AU2015202884A patent/AU2015202884B2/en active Active
- 2015-06-30 US US14/788,606 patent/US20150374732A1/en not_active Abandoned
2017
- 2017-03-02 JP JP2017039320A patent/JP6426778B2/ja active Active
- 2017-12-07 US US15/835,088 patent/US10220050B2/en active Active
2018
- 2018-03-15 RU RU2018109222A patent/RU2765076C2/ru active
2019
- 2019-01-09 US US16/244,014 patent/US10463683B2/en active Active
- 2019-01-16 HR HRP20190100TT patent/HRP20190100T1/hr unknown
- 2019-02-25 CY CY20191100231T patent/CY1121350T1/el unknown
- 2019-09-25 US US16/582,779 patent/US10646503B2/en active Active
2020
- 2020-01-21 HR HRP20200096TT patent/HRP20200096T1/hr unknown
- 2020-02-24 CY CY20201100168T patent/CY1122681T1/el unknown
- 2020-03-27 US US16/833,410 patent/US20200316099A1/en not_active Abandoned
2021
- 2021-09-02 HR HRP20211398TT patent/HRP20211398T1/hr unknown
- 2021-10-20 CY CY20211100917T patent/CY1124720T1/el unknown
- 2021-11-22 US US17/533,033 patent/US11571436B2/en active Active
- 2021-12-16 US US17/553,456 patent/US20220105118A1/en not_active Abandoned
2022
- 2022-11-10 US US17/984,939 patent/US20230241086A1/en not_active Abandoned
2023
- 2023-04-24 US US18/138,473 patent/US12053482B2/en active Active

Also Published As

Publication number	Publication date
HRP20231439T1 (hr)	2024-03-01
CA2761582C (en)	2022-06-07
HRP20190100T1 (hr)	2019-04-05
CA3094590A1 (en)	2009-11-19
SI3692983T1 (sl)	2021-11-30
US8846628B2 (en)	2014-09-30
RU2765076C2 (ru)	2022-01-25
RU2018109222A3 (pt)	2021-07-02
LT3782611T (lt)	2022-10-10
JP2015110575A (ja)	2015-06-18
CO6300930A2 (es)	2011-07-21
US20150374732A1 (en)	2015-12-31
EP3782612B1 (en)	2023-11-08
US20200316099A1 (en)	2020-10-08
AU2009246926B2 (en)	2014-06-26
HRP20221064T1 (hr)	2022-11-11
TW201006478A (en)	2010-02-16
PL3782612T3 (pl)	2024-03-04
SG193206A1 (en)	2013-09-30
EP3782612A1 (en)	2021-02-24
US10463683B2 (en)	2019-11-05
JP2011520880A (ja)	2011-07-21
PL3782611T3 (pl)	2022-11-07
US20180153916A1 (en)	2018-06-07
PL2695609T3 (pl)	2020-05-18
EP2299984B1 (en)	2018-11-28
ES2774226T3 (es)	2020-07-17
IL209307A0 (en)	2011-01-31
LT2299984T (lt)	2019-03-25
MY161593A (en)	2017-04-28
AU2015202884B2 (en)	2017-02-23
CR11789A (es)	2011-02-21
EP3782611B1 (en)	2022-07-06
ES2969144T3 (es)	2024-05-16
EP4327888A2 (en)	2024-02-28
IL209307A (en)	2016-02-29
HUE059635T2 (hu)	2022-12-28
MX2010012470A (es)	2010-12-02
CL2009001170A1 (es)	2010-06-04
US20220079964A1 (en)	2022-03-17
NZ589437A (en)	2012-11-30
US20090286752A1 (en)	2009-11-19
US20220105118A1 (en)	2022-04-07
AU2009246926A1 (en)	2009-11-19
TWI522103B (zh)	2016-02-21
US12053482B2 (en)	2024-08-06
HUE064677T2 (hu)	2024-04-28
ECSP10010665A (es)	2011-01-31
US20200101095A1 (en)	2020-04-02
CY1124720T1 (el)	2022-07-22
CN103479586B (zh)	2017-03-01
CN102099018B (zh)	2016-01-13
CN102099018A (zh)	2011-06-15
TWI618538B (zh)	2018-03-21
JP2017137326A (ja)	2017-08-10
RU2012147739A (ru)	2014-05-20
EP4327888A3 (en)	2024-05-22
LT3692983T (lt)	2021-11-10
EP3692983B1 (en)	2021-08-11
IL238087B (en)	2019-01-31
CA3094580C (en)	2021-05-18
NZ602833A (en)	2014-04-30
US20230255996A1 (en)	2023-08-17
EP3692983A1 (en)	2020-08-12
PT2695609T (pt)	2020-03-02
PL3692983T3 (pl)	2021-12-27
PT3692983T (pt)	2021-11-08
US10646503B2 (en)	2020-05-12
EP2299984A1 (en)	2011-03-30
AU2013202665B2 (en)	2015-06-25
DK2695609T3 (da)	2020-02-10
CY1122681T1 (el)	2020-10-14
LT2695609T (lt)	2020-02-10
EP3782611A1 (en)	2021-02-24
PL2299984T3 (pl)	2019-07-31
ES2893785T3 (es)	2022-02-10
PT3782611T (pt)	2022-11-18
CL2013001097A1 (es)	2013-11-29
TW201729817A (zh)	2017-09-01
EP2695609B1 (en)	2019-12-11
CA2761582A1 (en)	2009-11-19
SI3782611T1 (sl)	2022-10-28
CN103479586A (zh)	2014-01-01
TW201513869A (zh)	2015-04-16
NI201000193A (es)	2011-08-01
HRP20211398T1 (hr)	2021-12-10
US11571436B2 (en)	2023-02-07
BRPI0912717A2 (pt)	2014-12-23
DK2299984T3 (en)	2019-03-04
MX363023B (es)	2019-03-05
CY1121350T1 (el)	2020-05-29
AR071808A1 (es)	2010-07-14
CN105535008A (zh)	2016-05-04
JP6426778B2 (ja)	2018-11-21
JP6105547B2 (ja)	2017-03-29
PE20142440A1 (es)	2015-01-28
US20230241086A1 (en)	2023-08-03
DK3782612T3 (da)	2024-01-15
SI3782612T1 (sl)	2024-02-29
ZA201008229B (en)	2012-02-29
HUE047707T2 (hu)	2020-05-28
DK3692983T3 (da)	2021-09-20
ES2712506T3 (es)	2019-05-13
SI2299984T1 (sl)	2019-04-30
DK3782611T3 (da)	2022-09-05
HUE042825T2 (hu)	2019-07-29
KR20110015629A (ko)	2011-02-16
US10220050B2 (en)	2019-03-05
PT2299984T (pt)	2019-02-25
EP2695609A1 (en)	2014-02-12
SI2695609T1 (sl)	2020-03-31
HUE055911T2 (hu)	2021-12-28
CA3094580A1 (en)	2009-11-19
ES2927556T3 (es)	2022-11-08
AU2015202884A1 (en)	2015-06-18
LT3782612T (lt)	2023-12-27
RU2010151428A (ru)	2012-06-20
AU2013202665A1 (en)	2013-05-02
US20150056280A1 (en)	2015-02-26
HRP20200096T1 (hr)	2020-04-03
WO2009139888A1 (en)	2009-11-19
RU2018109222A (ru)	2019-09-17
RU2476207C2 (ru)	2013-02-27
KR101633134B1 (ko)	2016-06-23
NZ623495A (en)	2015-08-28
US20190231803A1 (en)	2019-08-01
PE20091971A1 (es)	2010-01-15
FI3782612T3 (fi)	2024-01-16

Publication	Publication Date	Title
HRP20190100T1 (hr)	2019-04-05	Oralne formulacije analoga citidina i postupci za njihovu upotrebu
EP2448406A4 (en)	2013-06-26	ORAL PHARMACEUTICAL COMPOSITIONS OF 3-HYDROXY-N-METHYLMORPHINAN WITH DELAYED RELEASE AND METHOD OF USE THEREOF
GB0915693D0 (en)	2009-10-07	Fatty acid formulations and methods of use thereof
PL2173345T3 (pl)	2016-01-29	Doustna formulacja metadoksyny
EP2001400A4 (en)	2013-01-23	ORAL FORMULATIONS OF GLYCYL-2-METHYLPROLYL-GLUTAMATE
ZA200905741B (en)	2010-06-30	Indenoisoquinolinone analogs and methods of use thereof
EP2170404A4 (en)	2011-01-19	COMPOSITIONS WITH HUMAN EGFR SIRNA AND METHOD OF USE
PL2285450T3 (pl)	2019-03-29	Kompozycje do higieny jamy ustnej i sposoby
IL213559A0 (en)	2011-07-31	Oral formulations
EP2310009A4 (en)	2011-10-19	PARENTERAL AND ORAL FORMULATIONS OF BENZIMIDAZOLES
ZA201100944B (en)	2012-07-25	Oral formulations of chemotherapeutic agents
EP2274325A4 (en)	2011-05-25	ANALOGUE OF HUMAN G-CSF AND METHOD OF MANUFACTURE AND APPLICATION THEREOF
IL210956A0 (en)	2011-04-28	Methionine analogs and methods of using same
TWM388323U (en)	2010-09-11	Improved structure of dental handpiece (1)